13 completed, 4 terminated, 4 unknown, 1 not yet recruiting. 22 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 13, Terminated 4, Unknown 4, Not yet recruiting 1 |
| Phase 2 | 8 | Completed 4, Unknown 3, Not yet recruiting 1 |
Follow Cross Infection: new trials by email Literature Review of Cross Infection trials Research Report on Cross Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision Modulation of Gut Microbiome Enteropathogen Colonization in Critical Illness Synbiotic, Standard of Care (SOC) - Critical Illness | Phase 1 / Phase 2 | Not yet recruiting | University of Calgary | 64 | 2027-01-01 | 2026-09-10 |
| Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia TP-122A - Pneumonia, Ventilator-Associated | Phase 1 / Phase 2 | Unknown | Technophage, SA | 15 | 2024-09-01 | 2024-04-17 |
| Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella acetyl cysteine 600 mg, antibiotics and saline. - Ventilator Associated Pneumonia ( VAP), Mechanical Ventilation | Phase 1 | Completed | Tanta University | 70 | 2023-10-30 | 2025-07-31 |
| Red Light Photobiomodulation and Topical Disinfectants Methylene Blue Only, Chlorhexidine Gluconate Only, Methylene Blue + Chlorhexidine Gluconate - Healthcare Associated Infection, Nosocomial Infection | Phase 1 / Phase 2 | Completed | Ondine Biomedical Inc. | 28 | 2023-01-10 | 2023-04-04 |
| Nebulised BromAc in Healthy Volunteers BromAc - COVID-19 Pneumonia, Bromelains Adverse Reaction | Phase 1 | Completed | Mucpharm Pty Ltd | 12 | 2022-07-27 | 2022-09-15 |
| Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease Bromelains, Acetylcysteine - COVID-19 Pneumonia, COVID-19 | Phase 1 / Phase 2 | Unknown | Mucpharm Pty Ltd | 30 | 2022-05-01 | 2022-02-28 |
| Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia Ceftazidime-avibactam - Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia | Phase 1 | Terminated | Pfizer | 4 | 2020-06-15 | 2022-09-09 |
| Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) Ceftolozane/Tazobactam - Nosocomial Pneumonia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 41 | 2020-04-17 | 2025-09-22 |
| Coated Devices to Decrease Infection in the Intensive Care Unit Coated devices, Control - Critically Ill | Phase 1 / Phase 2 | Completed | Hospital do Coracao | 103 | 2019-04-06 | 2020-03-09 |
| An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy Volunteers Fluorothyazinone 300 mg, Fluorothyazinone 600 mg, Fluorothyazinone 3900 mg - Healthy Volunteer | Phase 1 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 25 | 2017-08-10 | 2018-07-24 |
| Impact of Daily Bathing With Chlorhexidine in the Critical Patient Daily baths with chlorhexidine wipes, oral spray and standard shampoo, Daily baths with placebo wipes, oral spray and shampoo - Healthcare Associated Infections | Phase 1 | Unknown | Universidad Autonoma de Nuevo Leon | 40 | 2016-08-01 | 2016-08-17 |
| A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia gentamicin - Ventilator-associated Pneumonia | Phase 1 | Completed | Poitiers University Hospital | 12 | 2015-10-01 | 2017-03-24 |
| Aerosolized and Intravenous Colistin in Healthy Adults Colistimethate sodium - Pathogen Resistance, Pneumococcal Infection | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2013-08-06 | 2020-03-02 |
| Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor ticagrelor, placebo - Pneumonia, Community Acquired Pneumonia | Phase 1 | Completed | University of Kentucky | 60 | 2013-06-01 | 2018-09-13 |
| Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients Colistin 6 million units + 240mg/8h, Colistin 6 million units + 360mg/12h - Critical Illness | Phase 1 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 20 | 2011-10-01 | 2016-02-03 |
| Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants Talactoferrin, Placebo - Nosocomial Infections | Phase 1 / Phase 2 | Unknown | Agennix | 120 | 2009-06-01 | 2012-03-15 |
| Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia Ceftobiprole - Ventilator Associated Pneumonia | Phase 1 | Terminated | Basilea Pharmaceutica | 1 | 2008-10-01 | 2012-07-30 |
| Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa KB001, Placebo - Pseudomonas Aeruginosa, Ventilator Associated Pneumonia | Phase 1 / Phase 2 | Completed | Humanigen, Inc. | 36 | 2008-04-01 | 2009-07-31 |
| Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa KBPA-101 - Pneumonia, Ventilator Associated Pneumonia | Phase 1 / Phase 2 | Completed | Kenta Biotech Ltd | 15 | 2008-02-01 | 2009-07-30 |
| Probiotic Enteral Administration in Mechanically Ventilated Patients Ergyphilus - Pneumonia | Phase 1 | Terminated | Central Hospital, Nancy, France | 740 | 2006-01-01 | 2010-09-24 |
Showing 20 of 22. Sign in to see all of them.
Pneumonia, Ventilator-Associated (11) · Pneumonia (7) · Healthcare-Associated Pneumonia (6) · Critical Illness (3) · Pseudomonas Infections (2) · Sepsis (2) · Acute Lung Injury (1) · Bacteremia (1) · COVID-19 (1) · Cellulitis (1) · Clostridium Infections (1) · Community-Acquired Pneumonia (1) · Infections (1) · Medullary cystic kidney disease 1 (1)
Disease Attributes (22) · Iatrogenic Disease (22) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Infections (21) · Lung Diseases (17) · Respiratory Tract Diseases (17) · Respiratory Tract Infections (17) · Healthcare-Associated Pneumonia (10) · Pneumonia (10) · Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Inflammation (3) · Gram-Negative Bacterial Infections (2)
Acetylcysteine (2) · colistinmethanesulfonic acid (2) · Anti-Bacterial Agents (1) · Bromelains (1) · Gentamicins (1) · Oral Sprays (1) · Soaps (1) · Sodium Chloride (1) · Standard of Care (1) · Synbiotics (1) · Ticagrelor (1) · Toothbrushing (1) · avibactam, ceftazidime drug combination (1) · bromelain and acetylcysteine drug combination (1) · ceftobiprole (1)
Mucpharm Pty Ltd (2) · Agennix (1) · Basilea Pharmaceutica (1) · Central Hospital, Nancy, France (1) · Cook County Health (1) · Federal University of São Paulo (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Hospital do Coracao (1) · Humanigen, Inc. (1) · Kenta Biotech Ltd (1) · Merck Sharp & Dohme LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Ondine Biomedical Inc. (1) · Pfizer (1)
United States (6) · France (4) · Russia (2) · Spain (2) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Colombia (1) · Egypt (1) · Estonia (1) · Greece (1) · Mexico (1) · Switzerland (1)
Alexandre Biasi, MD/PhD (1) · Frank MP van Haren, MD, PhD (1) · Frank van Haren, MD, PhD (1) · Margarida Barreto, Msc (1) · Michel F Martinez-Resendez, M.D. (1) · Prof. Jean Chastre (1) · Robert A Weinstein, MD (1) · Sebastien Gibot, MD, PhD (1) · Susan S Smyth, MD PhD (1)
PMID 17954801, PMID 22497915, PMID 27234409, PMID 27260839, PMID 30175268, PMID 32526149
2018 (2), R44HD057744 (1)